Physician profile
Kush Sachdeva
NPI 1750372686
$14,881.98
in general payments reported to CMS, 2019-2025
76 companies · $2,822 in 2025
The $2,822 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $139 · 2021: $1,516 · 2022: $1,483 · 2023: $5,738 · 2024: $2,788 · 2025: $2,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,176 · Consulting Fee: $3,380 · Education: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,176.39 |
| Consulting Fee | $3,379.50 |
| Education | $791.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $3,479.98 | 2021-2023 | Padcev, Adcetris |
| Astrazeneca Pharmaceuticals Lp | $1,931.32 | 2020-2025 | Tagrisso, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $754.65 | 2019-2025 | |
| Pfizer INC. | $520.00 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $414.66 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Glaxosmithkline, LLC. | $394.11 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $377.83 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $333.56 | 2019-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $327.98 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $321.34 | 2020-2025 | Jakafi |
| Astellas Pharma US INC | $313.20 | 2022-2025 | Padcev |
| Gilead Sciences, INC. | $306.11 | 2021-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $283.28 | 2019-2024 | Soliris, Ultomiris |
| Genentech USA, INC. | $265.54 | 2019-2025 | Polivy, Tecentriq, Gazyva |
| Abbvie INC. | $251.09 | 2022-2025 | Venclexta |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $247.78 | 2019-2023 | Imbruvica, Epkinly |
| Celltrion USA INC. | $245.36 | 2023-2025 | Vegzelma |
| Eisai INC. | $237.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.55 | 2022-2025 | Fruzaqla, Alunbrig |
| Genzyme Corporation | $190.95 | 2019-2025 | |
| Sobi, INC | $179.35 | 2022-2025 | |
| Array Biopharma INC | $175.68 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $170.39 | 2022-2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $165.03 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $153.97 | 2021-2024 | Xpovio |
| Lilly USA, LLC | $142.08 | 2019-2025 | Verzenio, Jaypirca |
| Immunocore Limited | $136.73 | 2024-2025 | Kimmtrak |
| Spectrum Pharmaceuticals INC. | $132.37 | 2023-2025 | Rolvedon |
| Kite Pharma, INC. | $122.87 | 2019-2025 | Yescarta |
| Aveo Pharmaceuticals, INC. | $121.80 | 2022 | |
| Janssen Biotech, INC. | $117.08 | 2022-2025 | Tecvayli, Carvykti, Imbruvica |
| Exelixis INC. | $105.49 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $88.09 | 2021-2025 | Tevimbra, Brukinsa |
| Tempus Ai, INC | $85.48 | 2024-2025 | Xt Cdx |
| Stemline Therapeutics INC. | $80.70 | 2023-2025 | Orserdu |
| Beone Medicines USA, INC. | $70.63 | 2025 | Tevimbra, Brukinsa |
| Apellis Pharmaceuticals, INC. | $63.96 | 2023-2024 | Empaveli |
| Regeneron Healthcare Solutions, INC. | $63.14 | 2023-2025 | Libtayo |
| Amgen INC. | $61.51 | 2021-2023 | Nplate, Xgeva, Kyprolis |
| Invivyd INC | $61.36 | 2025 | Pemgarda |
| Emd Serono, INC. | $61.03 | 2022-2024 | Bavencio |
| Servier Pharmaceuticals LLC | $59.76 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $59.07 | 2021-2023 | Xarelto |
| Organon LLC | $57.19 | 2022-2024 | Ontruzant |
| Genmab U.S., INC. | $55.08 | 2022-2025 | Tivdak |
| Rigel Pharmaceuticals, INC. | $52.83 | 2023-2024 | Rezlidhia, Tavalisse |
| Jazz Pharmaceuticals INC. | $50.80 | 2025 | |
| Puma Biotechnology, INC. | $50.41 | 2024-2025 | |
| Acrotech Biopharma INC. | $45.49 | 2022-2025 | Ryzneuta |
| Novocure INC. | $45.16 | 2025 | Optune Lua (Novottf-200t) |
| Avyxa Pharma, LLC | $44.31 | 2025 | |
| Adc Therapeutics America, INC. | $41.67 | 2024-2025 | |
| Verity Pharmaceuticals INC. | $40.12 | 2023 | Trelstar |
| Pharmaand Gmbh | $39.53 | 2025 | Rubraca |
| Springworks Therapeutics, INC. | $39.16 | 2025 | Gomekli, Ogsiveo |
| Taiho Oncology, INC. | $37.60 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.57 | 2024-2025 | Gilotrif |
| Dova Pharmaceuticals | $35.11 | 2019-2020 | |
| Morphosys, US INC. | $32.21 | 2022-2023 | Monjuvi |
| Amneal Pharmaceuticals LLC | $31.26 | 2025 | Alymsys |
| Deciphera Pharmaceuticals INC. | $30.84 | 2022-2024 | Qinlock |
| Dendreon Pharmaceuticals LLC | $29.71 | 2024 | Provenge |
| Secura Bio, INC. | $27.07 | 2023 | Copiktra |
| Octapharma USA, INC. | $19.04 | 2019 | |
| Agios Pharmaceuticals, INC. | $18.86 | 2024 | Pyrukynd |
| Fennec Pharmaceuticals, INC. | $18.21 | 2025 | Fyarro |
| Cti Biopharma Corp. | $17.38 | 2022 | |
| Aadi Bioscience, INC. | $16.81 | 2023 | Fyarro |
| Tersera Therapeutics LLC | $16.57 | 2024 | Xermelo |
| Helsinn Therapeutics (U.S.), INC. | $15.98 | 2025 | Akynzeo |
| Foundation Medicine, INC. | $14.98 | 2019 | |
| Fresenius Kabi USA, LLC | $14.48 | 2022 | |
| Sumitomo Pharma America, INC. | $13.50 | 2025 | Orgovyx |
| Myovant Sciences INC. | $12.88 | 2022 | |
| Tesaro, INC. | $11.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kush Sachdeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.